MODULATION OF REGULATORY TOLERANCE TO TRANSPLANTS

调节移植的监管耐受性

• 批准号: 7570004
• 负责人: CHRISTIAN LEGUERN
• 金额: $ 53.06万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-03-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7570004
• 关键词: Adoptive Transfer; Alleles; Allografting; Animal Model; Animals; Antigen-Presenting Cells; Antigens; Autoantigens; Biological Assay; Biology; Blood; Blood Cells; Blood Tests; Bone Marrow; Cardiac; Cells; Characteristics; Cleaved cell; Clinical; Complementary DNA; Cyclosporine; Data; Development; Down-Regulation; Engineering; Ensure; Exhibits; Family suidae; Fibroblasts; Fostering; Foundations; Gene Transfer; Gene Transfer Techniques; Genes; Goals; Graft Rejection; Graft Survival; Haplotypes; Histology; Human; Hybrids; Immunity; Immunologics; Immunosuppression; Immunosuppressive Agents; In Vitro; Interleukin-2; Kidney; Kidney Transplantation; Knowledge; Lead; MHC Class II Genes; Maintenance; Mediating; Membrane; Miniature Swine; Minor; Modality; Modeling; Monitor; Mus; Patients; Pattern; Peptides; Pharmaceutical Preparations; Principal Investigator; Process; Production; Protocols documentation; Regulatory T-Lymphocyte; Research; Rest; Reverse Transcriptase Polymerase Chain Reaction; Role; Specificity; Surface; T-Cell Activation; T-Lymphocyte; T-Lymphocyte Subsets; Time; Tissue Grafts; Tissues; Transcript; Transfusion; Transgenes; Transgenic Organisms; Transplantation; Two-Dimensional Gel Electrophoresis; anergy; base; cell type; clinical application; cytokine; design; dimer; feeding; gene therapy; in vivo; kidney allograft; novel therapeutics; pre-clinical; programs; response; therapeutic development; transgene expression; vector

DESCRIPTION (provided by applicant): The development of "natural" immunosuppressive strategies to obviate T cell alloreactivity towards grafted tissues is a highly desirable alternative to non-specific, drug-mediated, T cell immunosuppression. We have shown, by gene transfer in a preclinical miniature swine kidney transplant model, that a partial donor/recipient match for a single MHC class II (CI2) molecule promotes spreading T cell tolerance to subsequent transgene-matched grafts and the down-regulation of host T cell activation to all graft-associated major and minor antigens. Given that 1) Partial CI2 matching also fosters regulatory tolerance to human transplants and 2) The miniature swine is the only animal model in which the role of CI2 in T cell tolerance can be reliably studied, the goal of this project is to elucidate, using the CI2 gene transfer pig model, the mechanism of regulatory T lymphocyte tolerance mediated by MHC CI2. This knowledge is a necessary prerequisite to the development of therapeutic protocols that activate the natural suppression of anti-graft responses in humans. Recent data using this approach indicate that CI2 transgenesis-mediated tolerance is associated with the down-regulation of T cell reactivity to the graft by regulatory T (T-reg) cells. In addition, transgenic CI2-derived peptides seem to be involved in the activation of T-reg cells which migrate to the graft. These findings suggest that Tg CI2 peptides fashion part of the host T-reg cell repertoire that may, subsequently, be activated by graft-matched CI2 to develop regulatory tolerance to the transplant. The present study intends to evaluate the importance of regulatory tolerance among other tolerogenic mechanisms leading to allograft acceptance. To this end, we will 1) Examine the effects of intracellular (peptides) and surface CI2 transgene expression on tolerance induction; 2) Assess the effects of CI2 transgene expression patterns on host immunity to Tg-matched kidney grafts and 3) Characterize the specificity and mode of action of T-reg-mediated suppression. It is hoped that these studies will provide the impetus for the design of new therapeutic molecules with clinical application in transplantation biology.

描述（由申请人提供）：开发“天然”免疫抑制策略以消除T细胞对移植物组织的同种异体反应性，是非特异性，药物介导的T细胞免疫抑制的非常理想的替代方案。我们已经通过在临床前微型猪肾移植模型中的基因转移表明，单个MHC II类（CI2）分子的部分供体/受体匹配促进了对随后的转基因匹配移植物的扩散T细胞耐受性，并下调了宿主T细胞对所有移植物相关的主要和次要抗原的激活。鉴于1)部分CI2匹配也能促进对人移植的调节性耐受，2)微型猪是唯一可以可靠研究CI2在T细胞耐受中的作用的动物模型，本项目的目标是利用CI2基因转移猪模型，阐明MHC CI2介导的调节性T淋巴细胞耐受的机制。这方面的知识是必要的先决条件，以发展治疗方案，激活人类抗移植物反应的自然抑制。最近使用这种方法的数据表明，CI2转基因介导的耐受性与调节性T细胞（T-reg）对移植物的T细胞反应性下调有关。此外，转基因ci2衍生肽似乎参与了T-reg细胞迁移到移植物的激活。这些发现表明Tg CI2肽形成宿主T-reg细胞库的一部分，随后可能被移植物匹配的CI2激活，以产生对移植的调节耐受性。本研究旨在评估调控耐受性在导致同种异体移植物接受的其他耐受性机制中的重要性。为此，我们将1)研究细胞内（肽）和表面CI2转基因表达对耐受性诱导的影响；2)评估CI2转基因表达模式对宿主对tg匹配肾移植免疫的影响；3)表征t -reg介导的抑制的特异性和作用方式。希望这些研究将为移植生物学中具有临床应用价值的新型治疗分子的设计提供动力。